Management of Asymptomatic Bacteriuria in Catheterized Patients

Introduction to Asymptomatic Bacteriuria

• The Infectious Diseases Society of America (IDSA) provides a strong recommendation against screening for or treating asymptomatic bacteriuria (ASB) in patients with indwelling urinary catheters, regardless of whether the catheter is short-term or long-term 1, 2, 3, 4, 5

Epidemiology of Bacteriuria

• All patients with indwelling catheters ultimately develop bacteriuria due to biofilm formation along the catheter surface 1, 2, 3
• Bacteriuria acquisition occurs at a rate of 3-5% per catheter day 1, 2, 3

Clinical Presentation and Diagnosis

• Only 7.7% of catheterized patients with bacteriuria develop any subjective symptoms 1, 2, 7
• Bacteremia directly attributable to catheter-associated bacteriuria occurs in only 0.5-0.7% of cases 1, 7
• Short-term catheter-associated bacteriuria does not increase risk for sepsis or death 1, 7

Treatment and Management

• Antimicrobial therapy only temporarily suppresses bacteriuria; recurrence with the same or different (often more resistant) organisms occurs universally 1, 2, 3
• The presence of >100,000 CFU/mL of bacteria does not distinguish infection from colonization in catheterized patients 1, 6
• Treatment may be warranted only in specific situations, such as planned urologic procedure with anticipated mucosal bleeding, pregnancy, or high-risk neutropenia 5, 9

Special Considerations

• The American College of Physicians and the IDSA recommend against treating ASB in catheterized patients, except in specific circumstances 1, 5, 9
• Catheter removal may clear bacteriuria in approximately 40% of patients 8

Evidence Quality and Strength

• The recommendation against treatment is based on strong evidence from the 2019 IDSA guidelines, including multiple prospective studies and a randomized controlled trial 1, 2, 3, 4, 5, 7